SiteTOP.org

www.celgene.es

Provided by Alexa ranking, www.celgene.es has ranked N/A in N/A and 6087851st on the world. It is hoted in N/A with IP address 18.173.121.40. The home page has 0 external link.

SiteTOP Score: 86347

SiteTOP Rank: 411180

Top keyword related from Search Engine of www.celgene.es

Traffic Ranks of www.celgene.es

Owner: N/A
RANK: 6087851
Country code: N/A
Country name: N/A
Rank on country: N/A
Host: N/A
Ip: 18.173.121.40
Ref link:
Extension: es

Top URL related to www.celgene.es

  • 1. Celgene: A Global Biopharmaceutical Company Committed to …

    celgene.com

    Link: https://www.celgene.com/?%2Fpatients%2F

    Description: WebLearn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the medical research to help people live longer, better, and healthier.

    DA: 78 PA: 94 MOZ Rank: 58

  • 2. REMS PATIENT SAFETY

    bmsremspatientsafety.com

    Link: https://www.bmsremspatientsafety.com/

    Description: WebTo avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID ® (thalidomide), POMALYST ® (pomalidomide), REVLIMID ® (lenalidomide) and generic lenalidomide. The THALOMID REMS ® program, Lenalidomide REMS program and POMALYST REMS ® program …

    DA: 28 PA: 78 MOZ Rank: 18

  • 3. Celgene - Wikipedia

    wikipedia.org

    Link: https://en.wikipedia.org/wiki/Celgene

    Description: WebCelgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.

    DA: 36 PA: 17 MOZ Rank: 26

  • 4. Global Biopharmaceutical Company - Bristol Myers Squibb

    bms.com

    Link: https://www.bms.com/

    Description: WebHelp paying for your medicines. If you are a patient in the U.S. struggling to understand your coverage or pay for your medication, we may be able to help. Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

    DA: 50 PA: 91 MOZ Rank: 51

  • 5. Bristol-Myers Squibb Completes Acquisition of Celgene, Creating …

    bms.com

    Link: https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Completes-Acquisition-of-Celgene-Creating-a-Leading-Biopharma-Company/default.aspx

    Description: WebNov 20, 2019 · NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by …

    DA: 89 PA: 29 MOZ Rank: 56

  • 6. Bristol-Myers Squibb to buy Celgene in $74 billion deal - CNN

    cnn.com

    Link: https://www.cnn.com/2019/01/03/business/bristol-myers-squibb-celgene-merger/index.html

    Description: WebJan 3, 2019 · New York CNN Business —. Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history. The deal, which ...

    DA: 22 PA: 94 MOZ Rank: 72

  • 7. Bristol-Myers to buy Celgene for $74 billion in largest biopharma …

    reuters.com

    Link: https://www.reuters.com/article/idUSKCN1OX0VM/

    Description: WebJan 4, 2019 · (Reuters) - Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical...

    DA: 72 PA: 42 MOZ Rank: 16

  • 8. Bristol Myers Squibb - Bristol-Myers Squibb to Acquire Celgene to

    bms.com

    Link: https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Acquire-Celgene-to-Create-a-Premier-Innovative-Biopharma-Company/default.aspx

    Description: WebJan 3, 2019 · In connection with the proposed transaction between Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) and Celgene Corporation (“Celgene”), Bristol-Myers Squibb and Celgene will file relevant materials with the Securities and Exchange Commission (the “SEC”), including a Bristol-Myers Squibb registration statement on …

    DA: 32 PA: 54 MOZ Rank: 28

  • 9. Celgene Corporation to Acquire Juno Therapeutics, Inc.

    celgene.com

    Link: https://www.celgene.com/newsroom/cellular-immunotherapies/celgene-corporation-to-acquire-juno-therapeutics-inc/

    Description: WebJan 22, 2018 · JCARH125 will enhance Celgene’s campaign against BCMA (B-cell maturation antigen), a key target in multiple myeloma. Additional cellular therapy assets in proof-of-concept trials for hematologic malignancies and solid tumors will add to Celgene’s existing pipeline.

    DA: 25 PA: 89 MOZ Rank: 98

  • 10. Bristol-Myers Squibb to Acquire Celgene for About $74 Billion

    wsj.com

    Link: https://www.wsj.com/articles/bristol-myers-squibb-to-acquire-celgene-11546517754

    Description: WebJan 3, 2019 · Bristol-Myers Squibb Co. BMY -0.87% agreed to buy rival Celgene Corp. in a deal valued at about $74 billion, combining two leading sellers of cancer drugs and potentially signaling the return of...

    DA: 29 PA: 80 MOZ Rank: 66